Cradle Genomics has developed a novel prenatal testing methodology that utilizes advanced genomic sequencing techniques to detect genetic abnormalities in fetuses. This technology provides expectant parents with early and accurate information about potential health issues, enabling informed decision-making during pregnancy.
Funding
$24.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Expectant parents often face uncertainty regarding the health of their unborn child, and current prenatal testing methods can be invasive or lack the sensitivity to detect certain genetic abnormalities early in pregnancy. This can lead to delayed diagnoses and increased anxiety for parents-to-be.
Solution
Cradle Genomics offers a non-invasive prenatal testing (NIPT) solution that leverages advanced genomic sequencing to identify potential fetal genetic abnormalities with high accuracy. Their methodology analyzes cell-free DNA circulating in the mother's blood to screen for a range of chromosomal disorders and genetic conditions. By providing early and reliable insights into the baby's health, Cradle Genomics empowers expectant parents and their healthcare providers to make informed decisions about prenatal care and potential interventions. The test aims to reduce the need for more invasive procedures while offering comprehensive genetic screening.
Target Audience
The primary target audience includes expectant parents seeking early and accurate information about their baby's genetic health, as well as obstetricians and other healthcare providers who offer prenatal screening services.
Features
- Utilizes cell-free DNA (cfDNA) sequencing technology for non-invasive screening.
- Detects chromosomal aneuploidies such as Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
- Screens for select sex chromosome aneuploidies.
- Offers optional screening for microdeletions and other genetic conditions.
- Provides results with high sensitivity and specificity, minimizing false positives and false negatives.
- Requires only a simple maternal blood draw.
- Offers rapid turnaround time for results reporting.